EyePoint, Inc. (EYPT) Earnings Call Transcripts

EyePoint, Inc.'s Latest Earnings Call - June 9, 2026

During EyePoint, Inc.'s earnings call for Q2 FY2026, management highlighted significant progress in their clinical programs, particularly the Phase III trials for their lead product, DURAVYU (EYP-1901), targeting wet AMD and DME. The company did not provide specific revenue or earnings figures in this call, focusing instead on clinical milestones and future guidance. Management reiterated that the LUGANO trial is on track for results in August 2026, with the LUCIA trial following shortly after. The diabetic macular edema trials, COMO and CAPRI, are expected to be fully enrolled by Q3 2026. The company maintained its guidance for cash runway into Q4 2027, covering all ongoing trials and commercial scale-up.

Reported metrics

Guidance from management

Management maintained guidance for cash runway into Q4 2027, covering all ongoing trials and commercial scale-up. They anticipate significant clinical milestones in the next 1.5 years, with LUGANO trial results expected in August 2026.

What management said

I think I mentioned this already that we do have preclinical data with some supporting clinical data from VERONA that we have an anti-inflammatory effect. And so we expect to see that in the Phase III trials. And if we can show it, the combination of an anti-VEGF that's anti-inflammatory that's given every 6 months, delivered in the office, shipped and stored at ambient temperature, I think that has the potential to ...

I don't think there's a single thing other than the whole story. We are a derisked asset with, we believe, very good Phase II data going into the 2 largest anti-VEGF markets, total of almost $13 billion in the United States alone with data readout coming very soon. We remain quite confident and quite optimistic in the results, and we think we can make a difference for patients. And so I think as people dig in and tur...

What analysts pressed on

Analysts expressed interest in the differentiation of DURAVYU compared to existing treatments and the potential commercial positioning. Concerns were raised about the competitive landscape and how EyePoint plans to position DURAVYU against established anti-VEGF therapies.

Main topics on the call

• Clinical Trials Progress — EyePoint is advancing its Phase III trials for DURAVYU in wet AMD and DME, with LUGANO results expected in August 2026. The diabetic macular edema trials are two-thirds enrolled and should be fully enrolled by Q3 2026. M...
• Differentiation of DURAVYU — DURAVYU offers a sustained release anti-VEGF effect for 6 months or longer with a single injection, differentiating it from other treatments that require more frequent dosing or surgical implantation. Management emphasiz...
• Anti-Inflammatory Benefits — The anti-inflammatory effects of DURAVYU, targeting the JAK1 receptor, were highlighted as a differentiator. Management noted, 'We should reduce the downstream effects of IL-6, which is an inflammatory pathway implicated...
• Phase III Trial Design — The Phase III trials are designed for non-inferiority to Eylea, with a focus on reducing treatment burden and achieving better vision outcomes. Management stated, 'Non-inferiority, again, to us is a derisking and it's th...

Read the full EyePoint, Inc. transcript (June 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 40 EyePoint, Inc. earnings call transcripts on record, spanning March 5, 2020 to June 9, 2026. Based on this history, EyePoint, Inc. reports quarterly. The most recent call on file is dated June 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

EYPT

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

40

First call

March 5, 2020

Most recent

June 9, 2026

Reporting cadence

quarterly